Evidence map›Paper›PMID 29971779›Full record

ArticleInternational journal of cancer2018

Pre-diagnostic circulating insulin-like growth factor-I and bladder cancer risk in the European Prospective Investigation into Cancer and Nutrition.

Crystal Lin, Ruth C Travis, Paul N Appleby, Sarah Tipper, Elisabete Weiderpass, Jenny Chang-Claude, Inger T Gram, Rudolf Kaaks, Lambertus A Kiemeney, Börje Ljungberg and 28 more

Open access · hybridAbstract readMulticenter Study
In one paragraph

Article in International journal of cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. The Sirenic Links between Diabetes, Obesity, and Bladder Cancer.International journal of molecular sciences · 2021
    Review
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors at 20 institutions in 13 countries.

Crystal LinCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
Ruth C TravisCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
Paul N ApplebyCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
Sarah TipperCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
Elisabete WeiderpassDepartment of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsø, Norway.
Jenny Chang-ClaudeGerman Cancer Research Center (DKFZ), Heidelberg, Germany.
Inger T GramFaculty of Health Sciences, Department of Community Medicine, University of Tromsø, The Arctic University of Norway, Tromsø, Norway.
Rudolf KaaksGerman Cancer Research Center (DKFZ), Heidelberg, Germany.
Lambertus A KiemeneyRadboud University Medical Center, Department for Health Evidence and Department of Urology, Nijmegen, The Netherlands.
Börje LjungbergDepartment of Surgical and Perioperative sciences, Urology and Andrology, Umeå University, Umeå, Sweden.
Rosario TuminoCancer Registry and Histopathology Department, "Civic - M. P. Arezzo" Hospital, Ragusa, Italy.
Anne TjønnelandDanish Cancer Society Research Center, Copenhagen Ø, Denmark.
Nina RoswallDanish Cancer Society Research Center, Copenhagen Ø, Denmark.ORCID 0000-0003-3071-1658
Kim OvervadAarhus University, Department of Public Health Section for Epidemiology, Aarhus, Denmark.
Marie-Christine Boutron-RuaultCESP, Faculté de Médecine, UVSQ, INSERM, Université Paris-Saclay, Villejuif, France.
Francesca Romana ManciniveriCESP, Faculté de Médecine, UVSQ, INSERM, Université Paris-Saclay, Villejuif, France.
Gianluca SeveriCESP, Faculté de Médecine, UVSQ, INSERM, Université Paris-Saclay, Villejuif, France.
Antonia TrichopoulouHellenic Health Foundation, Athens, Greece.
Giovanna MasalaCancer Risk Factors and Life-Style Epidemiology Unit, Cancer Research and Prevention Institute, ISPO, Florence, Italy.ORCID 0000-0002-5758-9069
Carlotta SacerdoteUnit of Cancer Epidemiology, Città della Salute e della Scienza University-Hospital and Center for Cancer Prevention (CPO), Turin, Italy.ORCID 0000-0002-8008-5096
Claudia AgnoliEpidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Salvatore PanicoDipartimento di Medicine Clinica e Chirurgia, Federico II University, Naples, Italy.
Bas Bueno-de-MesquitaDepartment for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
Petra H PeetersJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
Elena Salamanca-FernándezEscuela Andaluza de Salud Pública, Instituto de Investigación Biosanitaria ibs, GRANADA. Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain.
Maria-Dolores ChirlaqueCIBER Epidemiology and Public Health CIBERESP, Madrid, Spain.
Eva ArdanazCIBER Epidemiology and Public Health CIBERESP, Madrid, Spain.
Miren DorronsoroPublic Health Direction and Biodonostia Research Institute-Ciebersp, Basque Regional Health Department, Vitoria-Gasteiz, Spain.
Virginia MenéndezPublic Health Directorate, Asturias, Spain.
Leila Luján-BarrosoUnit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
Fredrik LiedbergDepartment of Translational Medicine, Lund University and Department of Urology, Skåne University Hospital, Malmö, Sweden.
Heinz FreislingSection of Nutrition and Metabolism, International Agency for Research on Cancer (IARC-WHO), Lyon, France.
Marc GunterSection of Nutrition and Metabolism, International Agency for Research on Cancer (IARC-WHO), Lyon, France.
Dagfinn AuneDepartment of Epidemiology and Biostatistics, The School of Public Health, Imperial College London, London, United Kingdom.
Amanda J CrossDepartment of Epidemiology and Biostatistics, The School of Public Health, Imperial College London, London, United Kingdom.
Elio RiboliDepartment of Epidemiology and Biostatistics, The School of Public Health, Imperial College London, London, United Kingdom.
Timothy J KeyCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
Aurora Perez-CornagoCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.ORCID 0000-0002-5652-356X
University of Oxford · GBInserm · FRCentre international de recherche sur le cancer · FRDanish Cancer Society · DKGerman Cancer Research Center · DEImperial College London · GBUniversity Medical Center Utrecht · NLAarhus University · DKAzienda Usl 8 Arezzo · ITBasque Government · ESFederico II University Hospital · ITFondazione IRCCS Istituto Nazionale dei Tumori · ITGobierno del Principado de Asturias · ESHellenic Health Foundation · GRInstitut d'Investigació Biomédica de Bellvitge · ESInstituto de Salud Pública de Navarra · ESInstituto Murciano de Investigación Biosanitaria · ESLund University · SEOslo Nye Høyskole · NOPiedmont Reference Center for Epidemiology and Cancer Prevention · IT

Funding

Cancer Research UK 14136C570/A11692Cancer Research UK 25004Cancer Research UK C570/A16491Cancer Research UK C8221/A19170Medical Research Council 1000143MR/M012190/1World Health Organization 001
6 · The paper itself

Abstract

Previous in vitro and case-control studies have found an association between the insulin-like growth factor (IGF)-axis and bladder cancer risk. Circulating concentrations of IGF-I have also been found to be associated with an increased risk of several cancer types; however, the relationship between pre-diagnostic circulating IGF-I concentrations and bladder cancer has never been studied prospectively. We investigated the association of pre-diagnostic plasma concentrations of IGF-I with risk of overall bladder cancer and urothelial cell carcinoma (UCC) in a case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. A total of 843 men and women diagnosed with bladder cancer between 1992 and 2005 were matched with 843 controls by recruitment centre, sex, age at recruitment, date of blood collection, duration of follow-up, time of day and fasting status at blood collection using an incidence density sampling protocol. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using conditional logistic regression with adjustment for smoking status. No association was found between pre-diagnostic circulating IGF-I concentration and overall bladder cancer risk (adjusted OR for highest versus lowest fourth: 0.91, 95% CI: 0.66-1.24, p

Indexed as

AdultAgedCase-Control StudiesEuropeFemaleHumansInsulin-Like Growth Factor IMaleMiddle AgedProspective StudiesRiskUrinary Bladder NeoplasmsIGF1 protein, humanInsulin-Like Growth Factor Ibladder cancerEPIC cohortIGF-Iprospectiveurothelial cell carcinoma

Identifiers

PMID29971779
PMCPMC6220964
OpenAlexW2813750132

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.